Eye drops: 0.3%
Eye ointment (preservative-free): 0.3%

SR capsules 40 mg

Specialist indication: drug of choice for ocular rosacea

UNLICENSED

Unlicensed

• 1.5% eye drops with and with out preservative are also approved -  unlicensed and

• For use in the treatment of acanthamoeba keratitis – used with PHMB.

• 0.1% and 0.3% eye drops.

• 100microgram in 0.1ml (0.1%) - preservative-free eye drops.

• 800mg Tablets
• For the treatment of ophthalmic zoster.

• 1% Eye drops

• 3.35 mg per 1 ml eye drops (0.4ml unit dose)
  • Approved for patients who require a preservative-free low potency ocular corticosteroid

ophthalmology advice only - second line if flurometholone unsuitable

• Preservative-free eye drops are also approved.
  
  • 0.1% Minims® - first choice.
  • 0.1% preservative free eye drops unlicensed - approved only for patients who are unable to use Minims®due to dexterity problems.
  
  

First choice

Unit dose vials (Minims®)

Alternative

Eye drops (unlicensed) - only for patients who are unable to use Minims® due to dexterity problems

• Eye drops and eye ointment

• For use in patients who experience ocular hypertension with other corticosteroids – treatment to be initiated with the advice of an ophthalmologist.

• Approved as a second line agent to conventional corticosteroid eye drops, treatment to be imitated with the advice of an ophthalmologist only.

• The following formulations are approved
  
  • 0.5% eye drops and 1% (Pred-Forte).
  • 0.1% and 0.3% eye drops - both unlicensed.
  
  
• Approved preservative free formulations include
  
  • 0.5% minims.
  • 0.1%, 0.3%, 0.5% and 1% - all unlicensed.
  
  

• Approved for macular oedema following central retinal vein occlusion
  in line with NICE.
• Approved for treating diabetic macular oedema in line with NICE.
• Approved for the treatment of non-infectious uveitis in line with NICE and NHS England Commissioning Policy

Note: The Northern (NHS) Treatment Advisory Group recommends the sequential pharmacological management of MO secondary to RVO as per the North East Retina Group (NERG) RVO treatment pathway.

• Recommended as a possible treatment for people with chronic diabetic macular oedema who have an artificial lens in their eye if the implant is used in the eye with the artificial lens and their diabetic macular oedema has not got better with other treatments - in line with NICE.
• Approved for the treatment of recurrent non-infectious uveitis in line with NICE
• Approved for treating chronic diabetic macular oedema in phakic eyes after an inadequate response to previous therapy in line with NICE
• Approved for treating chronic diabetic macular oedema in line with NICE

• Ikervis® - Approved for the treatment of dry eye disease in adults that has not improved despite treatment with artificial tears in line with NICE
• Verkazia® - Approved for the treatment of severe vernal keratoconjunctivitis in children from 4 years of age and adolescents

Ophthalmology advice - atopic keratoconjunctivitis

• A 2% preservative free preparation is also approved unlicensed -  treatment to be imitated with the advice of an ophthalmologist only.

• 40mg Injection
• Approved for the treatment of children with Severe Refractory Uveitis in line with interim NHS England Clinical Commissioning Policy.
• Approved for the treatment of non-infectious uveitis in line with NICE and NHS England Commissioning Policy (replaces interim policy for adalimumab for adults with severe refractory uveitis from 24th October 2017)

• 40mg in 1ml ophthalmic suspension injection
  
  
  
  • Approved for use in patients with pre-operative diabetic macular oedema (DMA) and epiretinal membrane undergoing vitreoretinal surgery
  
  
  
  

• Mydricaine® No.2 [Contains procaine hydrochloride 6mg, atropine sulphate 1mg, adrenaline 1:1,000; (0.12mg)]
• Approved for the treatment of anterior uveitis

• 0.5% and 1%.

• 0.5% and 1%.

• 2.5% eye drops unlicensed
• 2.5% single use Minims®

• 2.5% eye drops unlicensed.
• 2.5% single use Minims®.

Eye drops: 0.5%
Unit dose eye drops: 0.5%

• 0.25% and 0.5% eye drops.
  0.25% and 0.5% unit dose eye drops.

Eye drops: 40 micrograms/1 mL

Eye drops: travoprost 40 micrograms/1 mL, timolol 5 mg/1 mL (DuoTrav^®)

• For use as a second/third-line agent in patients insufficiently responsive
  to monotherapy with a prostaglandin analogue or beta blocker

• For use as a second/third-line agent in patients insufficiently responsive
  to monotherapy with a prostaglandin analogue or beta blocker.

• 0.2ml unit dose
• For use as a second/third-line agent in patients insufficiently responsive
  to monotherapy with a prostaglandin analogue or beta blocker.

• For use as an option for reducing intraocular pressure (IOP) in adults with primary open-angle glaucoma or ocular hypertension when a prostaglandin analogue alone has not reduced IOP enough, only if:
  • they have then tried a fixed-dose combination treatment and it has not reduced IOP enough, or
  • a fixed-dose combination treatment containing beta-blockers is unsuitable.

• Tafluprost 15micrograms/ml eye drops

• Tafluprost 15micrograms/ml eye drops 0.3ml unit dose preservative free

• Reserved for patients who cannot tolerate other prostaglandin analogues

• Approved as a third line agent as an “add-on” in patients at the very end of medical management.

• second line carbonic anhydrase inhibitor for glaucoma

• Eye drops and unit dose eye drops
• Approved for use in patients with confirmed allergy presenting as
  conjunctival changes or skin allergy. To be initiated by ophthalmologists
  only. The ophthalmologists must clearly document that signs and
  symptoms of preservative allergy have been demonstrated in their
  patient prior to initiation.

• 2% and 4% eye drops.
• 1% and 2% unit dose eye drops.

unlicensed P/F eye drops: 4%

Minims® eye drops (preservative free): 0.5%

• Viscous eyedrops
  
  
  
  • Approved for the treatment of corneal cystine deposits in people aged 2 years and over in line with NHS England Clinical Commissioning Policy 
  
  
  
  

Hydroxyethylcellulose Artifical Tears Minims 4.4mg per mL Minims Eye Drops

White soft paraffin and mineral oil

Eye drops: acetylcysteine 5%, hypromellose 0.35% (Ilube^®)

• Sterile solution containing sodium chloride 0.64%, sodium acetate 0.39%, sodium citrate 0.17%, calcium chloride 0.048%, magnesium chloride 0.03%, potassium chloride 0.075% in 15ml bottles and 500ml bags.
• For intra-ocular or topical irrigation during surgical procedures.

• Viscotears® eye drops
• GelTears® single unit dose eye drops

• 0.5% and 1% eye drops.

UNDER REVIEW

• Please note
  The brand name will soon change to Sooth Night-time and Duolube will be unable to be ordered

• Eye ointment (containing retinol palmitate (vitamin A) 250iu/g, white soft paraffin, light liquid paraffin, liquid paraffin and wool fat)

• 0.9% eye drops and single dose unit eye drops.
• 5% eye drops and preservative-free eye drops.
• 5% eye ointment unlicensed.

• 0.1% eye drops & preservative-free eye drops
• 0.2% eye drops & preservative-free eye drops
• 0.4% unit dose vials (Clinitas) & 0.4% preservative-free eye drops (Clinitas Multi) 

• 10ml multidose bottles 0.8ml preservative-free vials Contains hydroxypropyl guar, polyethylene glycol 400, propylene glycol (and other ingredients).
• Long-acting ocular lubricant used for the treatment of dry eye syndrome. Liquid formulation which turns into a gel on contact with eyes providing fast and long lasting relief. The multidose bottle may be used for up to six months after opening in primary care. In contact lens wearers, Systane should be applied before inserting lenses and after removal to extend comfortable wearing times.

• 2% minims eye drops
• 1mg ophthalmic strips
• Fluorets
• 10% 5ml & 20% 5ml injections unlicensed

25mg injection.

• 0.1% eye drops and unit dose eye drops.
• For post-operative inflammation limited to patients where corticosteroids are unsuitable.

• 20mg in 2ml injection.

• 0.5% and 1% ophthalmic solution.

• 0.5% eye drops.

• 1 mg/1mL eye drops

• For use in eye surgery only. 

• 10mg in 1ml bag (Z-Hyalin®, formerly Ophthalin Gelbag®)
• 14mg in 1ml syringe (Healon GV®)

• Injection for use in cataract surgery containing VisCoat (1% sodium hyaluronate) and ProVisc (3% sodium hyaluronate, 4% chondroitin sulphate).

• For use in the debridement of the corneal epithelium in patients with
  recurrent corneal erosion syndrome.

• 40mg/1ml & 114.3mg/1ml solution for injection
• Approved for wet age related macular degeneration in line with NICE.
• Approved for macular oedema – central retinal vein occlusion in line with NICE.
• Approved for diabetic macular oedema in line with NICE.
• Approved for treating visual impairment caused by macular oedema after branch retinal vein occlusion in line with NICE.
• Approved as an option for treating visual impairment because of myopic choroidal neovascularisation in adults in line with NICE

• 25 mg/mL solution for injection
• Approved for use as an option for treating wet age-related macular degeneration in adults in line with NICE

• 19.8mg/0.165mL solution for injection (pre-filled syringes)
  • Approved for treating wet age-related macular degeneration in adults in line with NICE

• 120mg/1ml solution for injection
  • Approved for the treatment of diabetic macular oedema in adults in line with NICE
  • Approved for the treatment of wet age-related macular degeneration in line with NICE
  • Approved for the treatment of visual impairment caused by macular oedema after retinal vein occlusion in line with NICE

• Approved for wet age related macular degeneration in line with NICE.
• Approved for diabetic macular oedema in line with NICE.
• Approved for visual impairment caused by macular oedema secondary
  to retinal vein occlusion in line with NICE.
• Approved as a possible treatment for sight problems caused by choroidal neovascularisation in people who also have pathological myopia in line with NICE.

Approved for photodynamic therapy in wet age-related macular degeneration in line NICE.

• NETAG approved for use in the management of macular oedema
  secondary to retinal vein occlusion. 

• NTAG approved for age related macular degeneration.

• Approved for use in patients with vitreomacular traction who also have no epiretinal membrane and a hole (up to 400 micrometres) in the centre of their retina or severe sight problems in line with NICE.

• Approved for treating limbal stem cell deficiency after eye burns in line with NICE and NHS England Commissioning Policy as of 14 November 2017

Intracameral injection: tropicamide 0.2 mg/mL, phenylephrine 3.1 mg/mL, lidocaine 10 mg/mL; 0.6 mL ampoules